IP Library Granted Patent US 7,732,599
Granted Patent B2
US 7,732,599 · App. 10/579,106 · Granted Jun 8, 2010

Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,732,599
App. No.
10/579,106
Granted
Jun 8, 2010
Kind
B2
Abstract

Process for the preparation of tetrahydrobiopterin from neopterin and/or 6-substituted pterins with an improved yield and a high stereoselectivity. Also disclosed herein are novel individual intermediates prepared in the preparation of tetrahydrobiopterin, such as selectively protected neopterin useful for the preparation of tetrahydrobiopterin.

Claims (10)

1. A process for forming enantiomerically-enriched tetrahydrobiopterin (BH4) or a salt thereof from neopterin, comprising the steps of:

(a) protecting the primary amine group at C-2 of neopterin with an amino protecting group;

(b) converting the primary hydroxyl group of neopterin to a thioether; and

(c) reducing the thioether of step (b) to a methyl group.

2. The process of claim 1 , wherein step (c) also results in removal of the primary amine protecting group and erythro-selective reduction to form BH4 or a salt thereof.

3. The process of claim 1 , wherein the erythro-selective reduction comprises using Raney nickel and hydrogen.

4. The process of claim 1 , further comprising the step of removing the primary amine protecting group after step (c).

5. The process of claim 4 , wherein the removing comprises reacting with zinc dichloride in ethanol.

6. The process of claim 4 , further comprising the step of performing an erythro-selective reduction to form BH4 or a salt thereof.

7. The process of claim 6 , wherein the erythro-selective reduction comprises using (1) sodium borohydride in an alkaline medium or (2) hydrogen and a catalytic amount of platinum dioxide.

Assignments (2)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2009
From: MERCK EPROVA AG
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 022145/0873 →